Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
ENCHANTED is an independent, investigator initiated, international collaborative,
 quasi-factorial randomised controlled trial involving a package of 2 linked comparative
 randomised treatment arms, which aims to address 4 key questions in patients eligible for
 thrombolysis in the acute phase of ischaemic stroke. (1) Does low-dose (0.6 mg/kg)
 intravenous (i.v.) recombinant tissue plasminogen activator (rtPA) provide equivalent
 benefits compared to standard-dose (0.9 mg/kg) rtPA? (2) Does intensive blood pressure (BP)
 lowering (130-140 mmHg systolic target) improve outcomes compared to the current guideline
 recommended level of BP control (180 mmHg systolic target)? (3) Does low-dose (0.6 mg/kg)
 intravenous (i.v.) recombinant tissue plasminogen activator (rtPA) reduce the risk of
 symptomatic intracerebral haemorrhage (sICH)? (4) Does the addition of intensive BP lowering
 to thrombolysis with rtPA reduce the risk of any intracerebral haemorrhage (ICH)?

 The rtPA dose arm of the study addressing questions (1) and (3) concluded with a publication
 of the results in May 2016. The BP intensity arm of the study addressing questions (2) and
 (4) concluded with a publication of the results in February 2019.
This study is an international, multicentre, prospective, fixed-time point (optional)
 randomisation for two arms ([A] 'dose of rtPA' and [B] 'level of BP control'), open-label,
 blinded endpoint (PROBE) controlled trial that involved 4587 patients (3310 for rtPA arm
 {recruitment completed in August 2015} and 2227 for BP arm {recruitment completed in April
 2018} with 939 overlap) with acute ischaemic stroke recruited from over 100+ Clinical Centres
 from Australia, Asia, Europe and South America.
Inclusion Criteria:

 -  Adult (age ≥18 years)

 -  A clinical diagnosis of acute ischaemic stroke confirmed by brain imaging

 -  Able to receive treatment within 4.5 hours after the definite time of onset of
 symptoms

 -  Have a systolic BP ≤185 mmHg

 -  Provide informed consent (or via an appropriate proxy, according to local
 requirements)

 Specific criteria for arm [A] of low-dose vs standard-dose rtPA (Recruitment completed in
 August 2015.):

 -  Able to receive either low-dose or standard-dose rtPA

 Specific criteria for arm [B] of intensive BP lowering vs guideline recommended BP control

 -  Patient will or has received thrombolysis treatment with rtPA, either randomised dose
 within the trial or physician decided dose rtPA outside of the trial

 -  Sustained elevated systolic BP level, defined as 2 readings ≥ 150 mmHg

 -  Able to commence intensive BP lowering treatment within 6 hours of stroke onset

 -  Able to receive either immediate intensive BP lowering or conservative BP management

 Exclusion Criteria:

 -  Unlikely to potentially benefit from the therapy (e.g. advanced dementia), or a very
 high likelihood of death within 24 hours of stroke onset.

 -  Other medical illness that interferes with outcome assessments and follow-up [known
 significant pre-stroke disability (mRS scores 2-5)].

 -  Specific contraindications to rtPA (Actilyse) or any of the blood pressure agents to
 be used.

 -  Participation in another clinical trial involving evaluation of pharmacological
 agents.

 -  Need for following concomitant medication, including phosphodiesterase inhibitors and
 monoamine oxidase inhibitors.